Novel Turbidimetric Immunoassay Evaluated for Fecal Calprotectin
|
By LabMedica International staff writers Posted on 28 Sep 2016 |
|
Image: The BS-380 automatic biochemistry analyzer (Photo courtesy of Mindray).
Calprotectin is a multifunctional protein that plays an important role in the diagnosis and follow-up of inflammatory bowel disease and high levels of calprotectin in stool samples are associated with inflammation of the intestinal tract.
Fecal calprotectin assays are widely used to exclude inflammatory bowel disease (IBD) in patients with suspected IBD, but the problem with most of the fecal calprotectin assays is the rather long test-turnaround times, before the results are available to the physician.
Scientists at Uppsala University (Sweden) optimized a particle enhanced turbidimetric immunoassay (PETIA) for fecal calprotectin and validated the assay for two clinical autoanalyzers using routine fecal samples. They compared the PETIA with a commercial enzyme-linked immunosorbent assay (ELISA), known as the Bühlmann fCAL ELISA (Bühlmann Laboratories, Schönenbuch, Switzerland). This new latex based turbidimetric calprotectin assay applies particles coated with anti-human calprotectin (MRP8/14) antibodies: the agglutination is proportional to the calprotectin concentration.
The fecal calprotectin PETIA was validated on two chemistry analyzers, the Mindray BS-380 (Mindray, Shenzhen, China) and the Cobas 501 (Roche Diagnostics, Basel, Switzerland). The assay is linear in the range 11 μg/g to 2,000 μg/g, with a limit of quantitation of approximately 10 μg/g. No antigen excess hook effect was observed up to 10,000 μg/g to 15,000 μg/g depending on the instrument used. The turbidimetric method showed a good agreement with the Bühlmann ELISA. The total coefficient of variation was 3% to 8% in the 50 μg/g to100 μg/g range.
The authors concluded that the fecal calprotectin PETIA, fCal Turbo, is well suited for rapid analysis of fecal calprotectin on Mindray BS-380 or Cobas 501 clinical chemistry analyzers. The test results are concordant with the Bühlmann fecal MRP8/14 ELISA. The study was published in the September 2016 issue of the Journal of Clinical Laboratory Analysis.
Related Links:
Uppsala University
Bühlmann Laboratories
Mindray
Roche Diagnostics
Fecal calprotectin assays are widely used to exclude inflammatory bowel disease (IBD) in patients with suspected IBD, but the problem with most of the fecal calprotectin assays is the rather long test-turnaround times, before the results are available to the physician.
Scientists at Uppsala University (Sweden) optimized a particle enhanced turbidimetric immunoassay (PETIA) for fecal calprotectin and validated the assay for two clinical autoanalyzers using routine fecal samples. They compared the PETIA with a commercial enzyme-linked immunosorbent assay (ELISA), known as the Bühlmann fCAL ELISA (Bühlmann Laboratories, Schönenbuch, Switzerland). This new latex based turbidimetric calprotectin assay applies particles coated with anti-human calprotectin (MRP8/14) antibodies: the agglutination is proportional to the calprotectin concentration.
The fecal calprotectin PETIA was validated on two chemistry analyzers, the Mindray BS-380 (Mindray, Shenzhen, China) and the Cobas 501 (Roche Diagnostics, Basel, Switzerland). The assay is linear in the range 11 μg/g to 2,000 μg/g, with a limit of quantitation of approximately 10 μg/g. No antigen excess hook effect was observed up to 10,000 μg/g to 15,000 μg/g depending on the instrument used. The turbidimetric method showed a good agreement with the Bühlmann ELISA. The total coefficient of variation was 3% to 8% in the 50 μg/g to100 μg/g range.
The authors concluded that the fecal calprotectin PETIA, fCal Turbo, is well suited for rapid analysis of fecal calprotectin on Mindray BS-380 or Cobas 501 clinical chemistry analyzers. The test results are concordant with the Bühlmann fecal MRP8/14 ELISA. The study was published in the September 2016 issue of the Journal of Clinical Laboratory Analysis.
Related Links:
Uppsala University
Bühlmann Laboratories
Mindray
Roche Diagnostics
Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Aspiration System
VACUSAFE
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
Automated Urinalysis Solution
UN-9000
Latest Clinical Chem. News
- Blood Biomarker Detects Alzheimer’s Changes Decades Before Symptoms in Down Syndrome
- Elevated Lipoprotein(a) Linked to Long-Term Progression of Carotid Atherosclerosis
- Study Questions Broad Fasting Requirements Before Routine Blood Tests
- Lollipop-Inspired Device Measures Acetaminophen Levels in Saliva
- New Insights Into Fetal DNA Could Improve Non-Invasive Prenatal Testing
- UK Project Advances Blood-Based Dementia Testing Toward Routine Clinical Care
- Noninvasive AI-Enabled Raman Probe Distinguishes Skin Cancers from Normal Tissue
- Screening After Pneumococcal Disease May Reveal Undiagnosed Blood Cancer or Immune Disorders
- Label-Free Platform Combines Microfluidics and AI for Circulating Tumor Cell Analysis
- Rapid D-Dimer Assay Supports Exclusion and Monitoring of Serious Clotting Conditions
- Global Survey Underscores Need to Standardize Bone Biomarker Testing
- Point-of-Care Blood Test Could Speed Treatment Decisions in Acute Stroke
- Noninvasive Earwax Test Aims to Detect Meniere’s Disease
- Blood Biomarker Patterns Could Support Monitoring of Anti-Amyloid Treatment
- Breath Analysis Shows Promise for Distinguishing Cancerous from Benign Lung Nodules
- Prehospital Blood Test Could Reduce Emergency Transfers for Chest Pain
Channels
Clinical Chemistry
view channel
Blood Biomarker Detects Alzheimer’s Changes Decades Before Symptoms in Down Syndrome
Alzheimer’s disease can begin altering the brain long before clinical symptoms appear, creating a challenge for early-stage detection and research. People with Down syndrome face a particularly high age-related... Read more
Study Questions Broad Fasting Requirements Before Routine Blood Tests
Routine blood testing is central to diagnosis, monitoring, and disease risk assessment. Many patients are still asked to fast for 8–12 hours before phlebotomy, even though the requirement was originally... Read more
Elevated Lipoprotein(a) Linked to Long-Term Progression of Carotid Atherosclerosis
Lipoprotein(a), or Lp(a), is a genetically determined blood lipid and an important risk factor for cardiovascular disease. Its relationship to long-term carotid atherosclerosis has remained unclear, particularly... Read more
Molecular Diagnostics
view channel
Genomic Screening Expands Detection of Treatable Conditions in Newborns
Conventional newborn screening can miss conditions that lack biochemical biomarkers or present atypically. Initial hearing screens may also fail to detect hearing loss that is later identified through... Read more
Age-Based Genetic Testing May Miss Most Inherited Cancer Risk Variants
Inherited cancer risk can influence diagnosis, treatment planning, and family screening, yet current testing practices often depend on a patient’s age at diagnosis. Many patients undergo germline genetic... Read more
New NGS Suite Expands Clonality and MRD Research in Lymphoid Malignancies
Lymphoid malignancies require molecular tools that can distinguish clonal immune receptor rearrangements and track disease-related sequences over time. As immune receptor measurable residual disease analysis... Read more
Tumor-Informed ctDNA Test Shows Utility Across Gastrointestinal and Gynecologic Cancers
Natera announced new data on Signatera, its tumor-informed circulating tumor DNA test, that were presented in four oral presentations at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.... Read moreHematology
view channel
New Donor Genetic Marker May Help Predict Stem Cell Transplant Success
Donor selection for hematopoietic stem cell transplantation plays a major role in relapse risk and survival for patients with blood cancers and other blood disorders. Despite advances in genotyping, uncertainty... Read more
Updated Ferritin Thresholds Improve Detection of Iron Deficiency
Iron deficiency is one of the most common health conditions worldwide, yet its nonspecific symptoms can delay diagnosis for months. Variation in testing practices and ferritin thresholds may contribute... Read more
Microbiology
view channel
Rapid Urine Test Aids Diagnosis of Invasive Aspergillosis
Invasive aspergillosis is an uncommon mold infection in the general population but can pose serious risks for people with weakened immune defenses. Diagnosis can be difficult because existing approaches... Read more
Nanodroplet CRISPR Technology Supports Rapid, Multiplexed Mycobacterial Identification
Mycobacterial infections are difficult to diagnose because closely related species can have different clinical and therapeutic implications. Nontuberculous mycobacteria (NTM) are increasingly recognized... Read more
Genomic Workflow Identifies Fungal Pathogens Before Blood Cultures Turn Positive
Fungal bloodstream infections pose a major threat to hospitalized patients. Candida species cause most invasive fungal infections worldwide and are among the leading causes of hospital-acquired bloodstream... Read more
FDA-Cleared Multiplex PCR Test Detects 13 Respiratory Pathogens in a Single Sample
Respiratory tract infections can be difficult to distinguish at presentation because many cause overlapping, nonspecific symptoms and are initially grouped as influenza-like illnesses. Causes span a range... Read morePathology
view channel
AI Histopathology Tool Distinguishes Ewing Sarcoma for Diagnosis
Ewing sarcoma is a rare malignant tumor that mainly affects children, adolescents, and young adults. It usually arises in bone but can also develop in soft tissue, where its microscopic appearance may... Read more
Rapid Mass Spectrometry Test May Aid Glioma Margin Decisions
Glioma brain tumors are highly infiltrative and can extend into nearby healthy brain tissue, making tumor margins difficult to define during surgery. Residual tumor cells may contribute to recurrence and... Read more
Genomic Classifier Predicts Benefit From Adding Hormone Therapy to Salvage Prostate Radiation
Men who have undergone prostatectomy for prostate cancer may later develop a detectable or rising prostate-specific antigen, prompting salvage radiation therapy. A key challenge is determining who is most... Read more
Technology
view channel
Laser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns
Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more
Laser-Enhanced Assay Boosts Sensitivity for Colorectal Cancer Biomarker Detection
Colorectal cancer is the third most commonly diagnosed cancer and the second leading cause of cancer-related death worldwide. Early detection remains critical, but cancer biomarkers can produce only faint... Read more
Industry
view channel
Regulatory Milestone Expands Access to Blood-Based Neurology Biomarker Testing in China
Quanterix Corporation (Billerica, MA, USA) and Innovita Biological Technology Co., Ltd. (Beijing, China) announced regulatory approvals that expand access to Quanterix SIMOA technology and neurology biomarker... Read more
Collaboration Advances Automated Benchtop Platform for Routine Blood Testing
Routine blood testing is central to clinical decision-making, but access can vary across laboratory and healthcare settings. Broader use of automated benchtop platforms may help integrate testing more... Read more
Expanded Partnership Supports AI Biomarker Validation and Clinical Trial Deployment
CellCarta (Montreal, Canada) and Imagene AI (Miami, FL, USA) have expanded their collaboration to provide biopharma companies with a coordinated pathway for biomarker strategy, assay development, validation,... Read more